SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 17.00 |
| Enterprise Value ($M) | 20.52 |
| Book Value ($M) | 0.71 |
| Book Value / Share | 0.01 |
| Price / Book | 24.05 |
| NCAV ($M) | -2.71 |
| NCAV / Share | -0.05 |
| Price / NCAV | -6.27 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -1.84 |
| Return on Assets (ROA) | -0.83 |
| Return on Equity (ROE) | -1.12 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.71 |
| Current Ratio | 4.77 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 47.91 |
| Assets | 51.33 |
| Liabilities | 50.62 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Basic And Diluted Calculated On Quarterly Basis | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D | Vifor (International) Ltd | 13.50 | 0.00 | |
| 13G/A | BlackRock, Inc. | 1.40 | -79.05 | |
| 13G/A | Bain Capital Life Sciences Opportunities III, LP | 0.00 | -100.00 | |
| 13G/A | Vanguard Group Inc | 4.83 | -15.17 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 149,529 | 496,241 | 30.13 | |
| 36,804 | 168,123 | 21.89 | |
| 76,977 | 202,507 | 38.01 | |
| 207,102 | 1,109,434 | 18.67 | |
| 58,679 | 788,731 | 7.44 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BYSI – BeyondSpring Inc. | CALC – CalciMedica, Inc. |
| CAPR – Capricor Therapeutics, Inc. | CASI – CASI Pharmaceuticals, Inc. |
| CDIO – Cardio Diagnostics Holdings, Inc. |